论文部分内容阅读
目的观察低分子肝素钠(克赛)治疗早期糖尿病肾病(DN)的临床疗效。方法对128例DN患者随机分为2组(每组为64例),治疗组Ⅰ采用常规降糖、降脂、降压等方法治疗;治疗组Ⅱ在常规降糖、降脂、降压等基础上加用低分子肝素钠进行治疗,疗程为4周。观察治疗前后尿蛋白定量(UP)、尿白蛋白排泄率(UAER)、血清肌酐(Scr)、血尿素氮(BUN)等指标变化。结果与治疗组Ⅰ相比,治疗组ⅡUP、UAER明显减少,差异显著(P<0.05),血清Scr、血BUN两组间差异不显著,整个疗程中未见明显不良反应。结论低分子肝素钠可降低早期DN患者的尿蛋白及尿白蛋白排泄率。
Objective To observe the clinical effect of low molecular weight heparin sodium on early diabetic nephropathy (DN). Methods A total of 128 patients with DN were randomly divided into 2 groups (64 in each group). The treatment group Ⅰ was treated with routine hypoglycemic, lipid-lowering and antihypertensive methods. The treatment group Ⅱ was given routine hypoglycemic, lipid-lowering, Based on the use of low molecular weight heparin for treatment, the course of treatment for 4 weeks. Urine protein (UAER), serum creatinine (Scr) and blood urea nitrogen (BUN) were measured before and after treatment. Results Compared with the treatment group Ⅰ, the levels of ⅡUP and UAER in the treatment group decreased significantly (P <0.05), but there was no significant difference between the two groups in the serum levels of Scr and blood BUN. No obvious adverse reactions were observed in the whole course of treatment. Conclusion Low molecular weight heparin can reduce urinary albumin and urinary albumin excretion rate in patients with early DN.